Ray Dalio’s TG Therapeutics TGTX Stock Holding History

Ray Dalio’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.3M	Sell	311,415 -158,440	-34%	-$4.72M	0.05%	259
2025 Q4	$14M	Buy	469,855 +127,706	+37%	+$4.17M	0.05%	270
2025 Q3	$12.4M	Buy	+342,149	New	+$11.3M	0.05%	293

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Ray Dalio's TGTX Position: Q1 2026 in Review

Ray Dalio reduced its TG Therapeutics (TGTX) stake by 34% in Q1 2026, selling an estimated $4.72M and leaving 311,415 shares worth $10.3M. The position accounts for 0.05% of the portfolio, ranked #259.

Ray Dalio first reported a position in TGTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $14M in Q4 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

Ray Dalio held 311,415 shares of TG Therapeutics worth $10.3M as of Q1 2026.
Ray Dalio sold 158,440 TG Therapeutics shares in Q1 2026, an estimated $4.72M.
TG Therapeutics made up 0.05% of Ray Dalio's portfolio in Q1 2026, its #259 holding.
Ray Dalio first reported a position in TG Therapeutics in Q3 2025 and has held it in 3 quarters since.
Ray Dalio's TG Therapeutics position peaked at $14M in Q4 2025.
363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.